Protocol Ledger

NCT06805305 · Phase II · RECRUITING

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Interventional Phase II clinical trial protocol NCT06805305 sponsored by Diakonos Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-17 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06805305
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06805305
Protocol FieldVerified Registry Value
NCT IdentifierNCT06805305
Consolidated Lead SponsorDiakonos Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2025-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI